摘要
免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)在恶性肿瘤治疗中广泛应用,其相关免疫不良反应(immune-related adverse events,irAEs)也日益受到关注。本文报道1例肝胆管恶性肿瘤患者使用帕博利珠单抗后出现免疫性膀胱炎的诊疗过程。患者因尿频、尿急、尿痛1个月入院,既往反复抗感染治疗无效,结合病史、实验室检查、影像学、膀胱镜及病理结果,最终临床诊断为ICIs(帕博利珠单抗)相关免疫性膀胱炎。予糖皮质激素治疗后患者症状显著缓解。本病例提示,临床医师需提高对ICIs相关泌尿系统irAEs的认识,早期识别、及时干预可显著改善患者预后。
Immune checkpoint inhibitors(ICIs)are widely used in the treatment of malignant tumors,and their related immune-related adverse events(irAEs)have attracted increasing attention.This study reports the diagnosis and treatment process of a case of immune cystitis in a patient with hepatobiliary tract malignant tumor after treatment with pembrolizumab.The patient was admitted to the hospital due to frequent urination,urgency of urination and dysuria for 1 month.Previous repeated anti-infection treatments were ineffective.Combined with medical history,laboratory tests,imaging findings,cystoscopy and pathological results,the patient was clinically diagnosed with ICIs-associated immune cystitis(Pembrolizumab)ultimately.The patient's symptoms significantly improved after treatment with glucocorticoids.This case reindicates that clinicians need to improve awareness of ICI-related urinary system irAEs.Early identification and timely intervention can significantly improve patient prognosis.
作者
余婧
李玲
陈文芳
文琼
陈崴
YU Jing;LI Ling;CHEN Wenfang;WEN Qiong;CHEN Wei(Department of Nephrology,NHC Key Laboratory of Clinical Nephrology(Sun Yat-sen University)and Guangdong Provincial Key Laboratory of Nephrology,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,China;Department of Pathology,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,China;Department of Nephrology,The People's Hospital of Bobai County,Yulin 537000,Guangxi,China)
出处
《协和医学杂志》
北大核心
2026年第2期396-402,共7页
Medical Journal of Peking Union Medical College Hospital
基金
国家自然科学基金(82370707,82570915,82200801)。
